We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Prescription medication — not a dietary supplement
Modafinilis a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Most Modafinil studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from medium-quality meta-analyses and randomised trials published 1998–2020 with a typical study size of 283 participants.
Based on 7 studies · 1 meta-analysis · 4 RCTs · 492 total participants
Confidence
ModerateBy outcome
Modafinil has an evidence score of 5/10 — emerging evidence based on 7 indexed studies, including 2 meta-analyses. A prescription wakefulness-promoting drug (Provigil) approved for the excessive daytime sleepiness of narcolepsy, shift-work sleep disorder, and residual sleepiness in treated obstructive sleep apnea. Widely used off-label as a 'smart drug' for cognition, but the cognitive benefit in healthy people is modest and task-dependent — and it carries a rare but serious skin-reaction (SJS/TEN) warning. A prescription drug, not a supplement, and not a longevity drug. Representative study: PMID 32709551.
The commonly studied dose of Modafinil is Approved dosing is 200 mg once daily in the morning for narcolepsy and OSA, or 200 mg taken ~1 hour before the start of a night shift for shift-work sleep disorder. A prescription drug; off-label cognitive use is not an approved or standardized regimen.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Armodafinil (Nuvigil)
Mostly mechanism / observationalA prescription wakefulness-promoting drug (Nuvigil) — the longer-acting R-enantiomer of modafinil — approved for the excessive sleepiness of narcolepsy, shift-work disorder, and residual sleepiness in treated obstructive sleep apnea. Used off-label as a 'smart drug' for wakefulness and cognition, but the off-label cognitive benefit in healthy people is modest and task-dependent (the same picture as modafinil), and it carries a rare but serious skin-reaction (SJS/TEN) warning. A prescription drug, not a supplement, and not a longevity drug.
Last reviewed June 2026 · evidence from 7 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Modafinil (Provigil) — wakefulness-promoting agent
A prescription wakefulness-promoting drug (Provigil) approved for the excessive daytime sleepiness of narcolepsy, shift-work sleep disorder, and residual sleepiness in treated obstructive sleep apnea. Widely used off-label as a 'smart drug' for cognition, but the cognitive benefit in healthy people is modest and task-dependent — and it carries a rare but serious skin-reaction (SJS/TEN) warning. A prescription drug, not a supplement, and not a longevity drug.
Modafinil has strong pivotal-RCT evidence for its approved sleep-disorder indications (narcolepsy, shift-work sleep disorder, residual sleepiness in treated OSA), but the popular off-label cognitive-enhancement use is supported only by modest, task-dependent effects in healthy adults (largest meta-analysis overall effect ~0.12), it is not a longevity drug, and it carries a rare but serious skin-reaction (SJS/TEN) warning — so the off-label use stays emerging.
Modafinil is a eugeroic — a wakefulness-promoting agent — that increases cortical catecholamine tone and indirectly raises orexin, histamine, glutamate, and serotonin signalling while lowering GABA, producing alertness through a profile distinct from amphetamine.
Its approved uses are well-evidenced: pivotal placebo-controlled RCTs in narcolepsy (the US Modafinil in Narcolepsy trials), in shift-work sleep disorder (Czeisler, NEJM 2005), and as an adjunct for residual excessive sleepiness in CPAP-treated obstructive sleep apnea (Black & Hirshkowitz, 2005) all show significant reductions in objective and subjective sleepiness.
Off-prescription, modafinil is taken widely as a cognitive enhancer or 'smart drug', and this is where the honest distinction matters: systematic reviews and meta-analyses in healthy, non-sleep-deprived adults find the cognitive benefit is MODEST and TASK-DEPENDENT — most consistent for executive function, attention, and memory updating under demanding or sleep-deprived conditions, smaller and inconsistent for simple tasks, with the largest 2020 meta-analysis reporting an overall effect size of only ~0.12 and concluding the user perception of strong enhancement 'is not supported by the evidence.' Modafinil is not a longevity or healthspan drug — there is no lifespan or geroprotective evidence.
Its abuse and dependence liability is low relative to classic stimulants, but it is not benign: the label carries a boxed/serious warning for rare but life-threatening skin reactions (Stevens-Johnson syndrome and toxic epidermal necrolysis), plus psychiatric effects, and it induces CYP3A4 (reducing hormonal contraceptive efficacy).
The score reflects genuinely strong evidence for its approved sleep-disorder indications against a modest, task-dependent off-label cognitive benefit and real serious-rash risk.
Increases cortical catecholamine levels (weak dopamine-transporter inhibition raising synaptic dopamine and noradrenaline) — the core of its wake-promoting action.
Indirectly activates orexin (hypocretin) neurons and the tuberomammillary histamine system, engaging the brain's intrinsic arousal pathways.
Effects favour prefrontal-dependent processes — working/episodic memory and executive control — over subcortical sites, underlying the task-dependent cognitive effects.
How Modafinil works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Tap node to isolate • Pinch to zoom • Tap edge for research
Approved dosing is 200 mg once daily in the morning for narcolepsy and OSA, or 200 mg taken ~1 hour before the start of a night shift for shift-work sleep disorder. A prescription drug; off-label cognitive use is not an approved or standardized regimen.
Can be taken without food
| Form | Type |
|---|---|
| 💊Oral tablet (modafinil) | Recommended |
| 💊Armodafinil (longer-acting R-enantiomer, similar indications) | Alternative |
Modafinil is the racemate with the deepest trial base across narcolepsy, shift work, and OSA.
Compare Modafinil vs Armodafinil (Nuvigil) →Minimum: 1 weeks
Optimal: 9 weeks
Cycling: Not required
Note: Once daily in the morning for narcolepsy/OSA, or before a night shift for shift-work disorder; avoid late-day dosing because of the long half-life.
Dose-response data unavailable. The current published research for Modafinil does not provide sufficient dose-specific outcome data to generate reliable dose-response curves.
Refer to the Dosage & Timing section above for recommended dose ranges based on available evidence.
In narcolepsy, shift-work sleep disorder, and treated OSA, modafinil significantly improves objective wakefulness (Maintenance of Wakefulness Test) and subjective sleepiness.
In healthy adults, benefits are modest and task-dependent — most consistent for executive function, attention, and memory updating under demanding or sleep-deprived conditions.
The largest meta-analysis found an overall effect of only ~0.12 in healthy non-sleep-deprived adults — the popular 'smart drug' reputation outruns the evidence.
Headache, insomnia, and anxiety are common; rare but life-threatening skin reactions (SJS/TEN) and psychiatric effects can occur.
Use additional/alternative contraception during and for ~1 month after modafinil (CYP3A4 induction lowers efficacy).
Use with caution — modafinil can precipitate mania, psychosis, or anxiety.
Caution with uncontrolled hypertension or arrhythmia; monitor blood pressure and heart rate.
Modafinil induces CYP3A4 and can reduce contraceptive efficacy — additional/alternative contraception is advised during and for ~1 month after use.
Inhibits CYP2C19 and alters other enzymes — can raise levels of warfarin, phenytoin, and similar drugs; monitor.
Tip: Most frequent adverse effect in trials; often dose-related and transient.
Tip: Dose in the morning; reduce dose if sleep or anxiety is affected.
Tip: Stop immediately and seek emergency care at the first sign of rash, blistering, or mucosal involvement; risk is highest early in treatment.
Tip: Caution in those with a psychiatric history; discontinue and seek care if new psychiatric symptoms emerge.
The best time to take Modafinil is in the morning. It can be taken on an empty stomach. Long half-life (~12–15 h) means morning dosing avoids disrupting nighttime sleep; shift-work use is dosed before the shift.
Modafinil should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are headache, insomnia / anxiety / nervousness, serious skin reaction (Stevens-Johnson syndrome / TEN). Use caution if any of these apply to you: Prior hypersensitivity or serious skin reaction to modafinil/armodafinil; History of left ventricular hypertrophy or mitral valve prolapse with prior stimulant use; Uncontrolled hypertension or arrhythmia (use with caution).
Adrafinil (Olmifon)
Mostly mechanism / observationalA discontinued French wakefulness drug (Olmifon, CRL-40028) the liver converts into modafinil — essentially a less-efficient, slower way to take modafinil. Once prescribed for vigilance and attention in the elderly, it was withdrawn from the market and now circulates grey-market as an unregulated 'nootropic.' Direct human evidence is old and thin, chronic use can raise liver enzymes, and it is NOT a dietary supplement and NOT a longevity drug.
Additive cardiovascular and CNS stimulation; use with caution.